127 Tau PET and cognition in early- and late onset AD 18. Golla, S.S., et al., Parametric methods for [18F] flortaucipir PET. Journal of Cerebral Blood Flow & Metabolism, 2020. 40(2): p. 365-373. 19. Peretti, D.E., et al., Relative cerebral flow from dynamic PIB scans as an alternative for FDG scans in Alzheimer’s disease PET studies. PloS one, 2019. 14(1): p. e0211000. 20. Rodriguez-Vieitez, E., et al., Comparability of [18F] THK5317 and [11C] PIB blood flow proxy images with [18F] FDG positron emission tomography in Alzheimer’s disease. Journal of Cerebral Blood Flow & Metabolism, 2017. 37(2): p. 740-749. 21. Peretti, D.E., et al., Diagnostic performance of regional cerebral blood flow images derived from dynamic PIB scans in Alzheimer’s disease. EJNMMI research, 2019. 9(1): p. 1-9. 22. Joseph-Mathurin, N., et al., Utility of perfusion PET measures to assess neuronal injury in Alzheimer’s disease. Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring, 2018. 10: p. 669-677. 23. Chen, Y.J., et al., Relative 11C-PiB delivery as a proxy of relative CBF: quantitative evaluation using single-session 15O-water and 11C-PiB PET. Journal of Nuclear Medicine, 2015. 56(8): p. 1199-1205. 24. Ottoy, J., et al., 18F-FDG PET, the early phases and the delivery rate of 18F-AV45 PET as proxies of cerebral blood flow in Alzheimer’s disease: Validation against 15O-H2O PET. Alzheimer’s & Dementia, 2019. 15(9): p. 1172-1182. 25. Wolters, E.E., et al., Tau pathology, relative cerebral flow and cognition in dementia with Lewy bodies: Tau imaging. Alzheimer’s & Dementia, 2020. 16: p. e041048. 26. Spina, S., et al., Comorbid neuropathological diagnoses in early versus late-onset Alzheimer’s disease. Brain, 2021. 27. McKhann, G.M., et al., The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimer’s & dementia, 2011. 7(3): p. 263-269. 28. Albert, M.S., et al., The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Focus, 2013. 11(1): p. 96-106. 29. van der Flier, W.M., et al., Optimizing patient care and research: the Amsterdam Dementia Cohort. Journal of Alzheimer’s disease, 2014. 41(1): p. 313-327. 30. Crutch, S.J., et al., Posterior cortical atrophy. The Lancet Neurology, 2012. 11(2): p. 170-178. 31. Ossenkoppele, R., et al., The behavioural/dysexecutive variant of Alzheimer’s disease: clinical, neuroimaging and pathological features. Brain, 2015. 138(9): p. 2732-2749. 32. Tijms, B.M., et al., Unbiased approach to counteract upward drift in cerebrospinal fluid amyloid-β 1–42 analysis results. Clinical Chemistry, 2018. 64(3): p. 576-585. 33. Duits, F.H., et al., The cerebrospinal fluid “Alzheimer profile”: easily said, but what does it mean? Alzheimer’s & Dementia, 2014. 10(6): p. 713-723. e2. 34. Mendez, M.F., et al., Nonamnestic presentations of early-onset Alzheimer’s disease. American Journal of Alzheimer’s Disease & Other Dementias®, 2012. 27(6): p. 413-420. 35. Crutch, S.J., et al., Consensus classification of posterior cortical atrophy. Alzheimer’s & Dementia, 2017. 13(8): p. 870-884. 5
RkJQdWJsaXNoZXIy MjY0ODMw